What's new this week?

This week you can discover more about the first Union list of critical medicines, the follow-up data from the Phase IIb clinical trial evaluating cancer vaccine and Vertex Pharmaceuticals' gene-editing therapy Casgevy?.

You can also hear from Innate Pharma’s Yannis Morel as he delves into the unique advantages of using multi-specific antibodies capable of engaging NK cells against tumours for oncology indications.

Watch experts from Curia discuss trends in the pharmaceutical industry, including the move to adopt continuous flow chemistry processes for both mRNA and small molecule manufacturing. We hope you find it useful!

Trending news from the industry:

The European Commission , the Heads of Medicines Agencies (HMA) and the European Medicines Agency (EMA) have published the first Union list of critical medicines. The list contains more than 200 active substances that are considered “critical for healthcare systems” across the EU/EEA. Continuity of supply is seen as a priority for these substances and shortages should be avoided. Read more here.

Moderna and MSD have announced follow-up data from the Phase IIb clinical trial evaluating cancer vaccine mRNA-4157 (V940) in combination with MSD’s Keytruda in patients with resected high-risk melanoma. Read more here.

The European Medicines Agency ’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the conditional approval of Vertex Pharmaceuticals ' gene-editing therapy Casgevy? for the treatment of severe sickle cell disease and transfusion-dependent beta thalassemia. Read more here.

In this interview, Innate Pharma ’s Yannis Morel , Executive Vice President of product portfolio strategy and business development, delves into the unique advantages of using multi-specific antibodies capable of engaging NK cells against tumours for oncology indications, and shares key data from the company’s ongoing and recent clinical trials. Read more here.

What to read:

Quick to spread and difficult to detect, moulds can compromise a facility in the time it takes to confirm their presence. Find out more about the RMBNucleus Mold Alarm.

Discover from Courtney Wachtel the newest animal-free endotoxin testing solution! Download this article to discover more about the stability profile for Trillium, the critical parameters for an rCR and how the Trillium recombinant cascade agent is different from naturally occurring LAL. Read more here.

What to watch:

New webinar for 2024! Solve your dosage form and delivery challenges with Lonza Capsules & Health Ingredients . Register your place now.

In this video, experts from Curia discuss trends in the pharmaceutical industry, including the move to adopt continuous flow chemistry processes for both mRNA and small molecule manufacturing. Watch now.

What to listen to:

Hear from Paul Nioi , Vice President of Discovery and Translational Research at Alnylam Pharmaceuticals , discusses the clinical development and manufacturing of RNA interference therapeutics. Listen now.

European Pharmaceutical Review is an essential resource for students, researchers and industry professionals looking for the latest industry insights and innovations. Sign up for free now.